NCT07739186
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)
At risk: Primary endpoint(s) modified.
See at-risk trials from Sichuan Baili Pharmaceutical Co., Ltd.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Nov 2026 to Oct 21, 2026
- Site details revised at 2 of 2 sites
Notable Start date: Aug 2026 to Nov 2026 Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 43 words
- Enrollment increased: 120 → 166 participants
- Interventions: BL-B01D1 (Drug), Carboplatin (Drug), Cisplatin (Drug), PD-1/VEGF Bispecific Antibody (Drug), Pemetrexed (Drug), Tislelizumab (Drug) to BL-B01D1 (Drug), Carboplatin (Drug), Cisplatin (Drug), PD-1/VEGF Bispecific Antibody (Drug), Pemetrexed (Drug), Tislelizumab (Drug)
- Secondary endpoints revised (13)
- Minor Site contacts updated at 2 of 2 sitesv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Participants receive BL-B01D1 + PD-1/VEGF Bispecific Antibody in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Participants receive PD-1/VEGF Bispecific Antibody + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Participants receive Tislelizumab + Pemetrexed + Carboplatin or Cisplatin in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
Drugs: BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab, Pemetrexed, Carboplatin, Cisplatin
Sites
2 sites in 1 country